Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

AIMS: In patients with current or a history of hyperkalaemia, treatment with renin–angiotensin–aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K(+)) binder, may improve serum K(+) levels and adherence to RAASi. METHODS: The DIAMOND trial will enroll ∼820 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Javed, Anker, Stefan D., Siddiqi, Tariq Jamal, Coats, Andrew J.S., Dorigotti, Fabio, Filippatos, Gerasimos, Friede, Tim, Göhring, Udo‐Michael, Kosiborod, Mikhail N., Lund, Lars H., Metra, Marco, Moreno Quinn, Carol, Piña, Ileana L., Pinto, Fausto J., Rossignol, Patrick, Szecsödy, Peter, Van Der Meer, Peter, Weir, Matthew, Pitt, Bertram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300159/
https://www.ncbi.nlm.nih.gov/pubmed/34800079
http://dx.doi.org/10.1002/ejhf.2386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300159/
https://www.ncbi.nlm.nih.gov/pubmed/34800079
http://dx.doi.org/10.1002/ejhf.2386

Ejemplares similares